Riccardo Magistroni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3984890/publications.pdf

Version: 2024-02-01

73 papers	5,720 citations	172207 29 h-index	114278 63 g-index
83 all docs	83 docs citations	83 times ranked	6378 citing authors

#	Article	IF	Citations
1	Acid base disorders in patients with COVID-19. International Urology and Nephrology, 2022, 54, 405-410.	0.6	26
2	Artificial intelligence in glomerular diseases. Pediatric Nephrology, 2022, 37, 2533-2545.	0.9	7
3	Ethical challenges in managing unvaccinated patients receiving chronic in-centre haemodialysis. CKJ: Clinical Kidney Journal, 2022, 15, 615-617.	1.4	4
4	Reactogenicity of COVID-19 vaccine in hemodialysis patients: a single-center retrospective study.. Giornale Italiano Di Nefrologia: Organo Ufficiale Della Società Italiana Di Nefrologia, 2022, 39, .	0.3	0
5	MO137: Sarcoidosis in a Living Kidney Donor Candidate: Case Report and Review of the Literature. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
6	The Role of the Renin-Angiotensin System in Severe Acute Respiratory Syndrome-CoV-2 Infection. Blood Purification, 2021, 50, 263-267.	0.9	17
7	Confidence Calibration for Deep Renal Biopsy Immunofluorescence Image Classification. , 2021, , .		5
8	Hypokalemia in Patients with COVID-19. Clinical and Experimental Nephrology, 2021, 25, 401-409.	0.7	78
9	Seroconversion after COVID-19 vaccine in a dialysis patient on immunosuppressants. CKJ: Clinical Kidney Journal, 2021, 14, 1983-1984.	1.4	4
10	Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 972-982.	3.0	103
11	Clinical Presentation, Renal Histopathological Findings, and Outcome in Patients with Monoclonal Gammopathy and Kidney Disease. International Journal of Nephrology, 2021, 2021, 1-9.	0.7	2
12	Monoclonal B lymphocytosis in a kidney transplant recipient. BMJ Case Reports, 2021, 14, e242889.	0.2	0
13	Twenty-four-hour serum creatinine variation is associated with poor outcome in the novel coronavirus disease 2019 (COVID-19) patients. Kidney Research and Clinical Practice, 2021, 40, 231-240.	0.9	14
14	Response letter to the Editorial: "Ketogenic diet in ADPKD patients". PharmaNutrition, 2021, 16, 100268.	0.8	2
15	Oneâ€year persistence of neutralizing <scp>antiâ€</scp>SARSâ€CoVâ€2 antibodies in dialysis patients recovered from COVIDâ€19. Hemodialysis International, 2021, 25, E53-E56.	0.4	8
16	Clinical Predictors of Nondiabetic Kidney Disease in Patients with Diabetes: A Single-Center Study. International Journal of Nephrology, 2021, 2021, 1-7.	0.7	7
17	Incidence, risk factors and outcome of acute kidney injuryÂ(AKI) in patients with COVID-19. Clinical and Experimental Nephrology, 2021, 25, 1203-1214.	0.7	27
18	The frail world of haemodialysis patients in the COVID-19 pandemic era: a systematic scoping review. Journal of Nephrology, 2021, 34, 1387-1403.	0.9	24

#	Article	IF	Citations
19	Methicillin-Resistant Staphylococcus aureus Peritonitis due to Hematogenous Dissemination from Central Venous Catheter in a Maintenance Dialysis Patient. Case Reports in Nephrology and Dialysis, 2021, 11, 281-285.	0.3	1
20	Acid base disorders in patients with COVID-19. International Urology and Nephrology, 2021, , .	0.6	4
21	AKI in hospitalized patients with COVID-19: a single-center experience. Giornale Italiano Di Nefrologia: Organo Ufficiale Della Società Italiana Di Nefrologia, 2021, 38, .	0.3	0
22	Immunosuppressive therapy reduction and early post-infection graft function in kidney transplant recipients with COVID-19.. Giornale Italiano Di Nefrologia: Organo Ufficiale Della Società Italiana Di Nefrologia, 2021, 38, .	0.3	0
23	ADPKD current management and ongoing trials. Journal of Nephrology, 2020, 33, 223-237.	0.9	16
24	Hybrid dialysis: a promising strategy to reduce hospital access during the SARS-CoV-2 pandemic. BMJ Case Reports, 2020, 13, e236411.	0.2	1
25	Severe acute respiratory SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience. CKJ: Clinical Kidney Journal, 2020, 13, 334-339.	1.4	19
26	Oxalate Nephropathy Caused by Excessive Vitamin C Administration in 2 Patients WithÂCOVID-19. Kidney International Reports, 2020, 5, 1815-1822.	0.4	45
27	Longâ€term effects of COVID â€19 in a patient on maintenance dialysis. Hemodialysis International, 2020, 24, E50-E54.	0.4	9
28	GREASE II. A phase II randomized, 12-month, parallel-group, superiority study to evaluate the efficacy of a Modified Atkins Diet in Autosomal Dominant Polycystic Kidney Disease patients. PharmaNutrition, 2020, 13, 100206.	0.8	10
29	Evaluation of the Classification Accuracy of the Kidney Biopsy Direct Immunofluorescence through Convolutional Neural Networks. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1445-1454.	2.2	34
30	COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine. American Journal of Transplantation, 2020, 20, 1902-1906.	2.6	81
31	Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool. Kidney International, 2020, 98, 1009-1019.	2.6	35
32	OUP accepted manuscript. CKJ: Clinical Kidney Journal, 2020, 13, 265-268.	1.4	16
33	TRPP2 dysfunction decreases ATP-evoked calcium, induces cell aggregation and stimulates proliferation in T lymphocytes. BMC Nephrology, 2019, 20, 355.	0.8	12
34	A pilot study to evaluate tolerability and safety of a modified Atkins diet in ADPKD patients. PharmaNutrition, 2019, 9, 100154.	0.8	13
35	Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial. BMJ Open, 2019, 9, e029232.	0.8	11
36	A Review of the Imaging Techniques for Measuring Kidney and Cyst Volume in Establishing Autosomal Dominant Polycystic Kidney Disease Progression. American Journal of Nephrology, 2018, 48, 67-78.	1.4	51

#	Article	IF	Citations
37	The prevalence of autosomal dominant polycystic kidney disease (ADPKD): A meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition. PLoS ONE, 2018, 13, e0190430.	1.1	57
38	Comparison of Total Kidney Volume Quantification Methods in Autosomal Dominant Polycystic Disease for a Comprehensive Disease Assessment. American Journal of Nephrology, 2017, 45, 373-379.	1.4	12
39	Defective glycolysis and the use of 2-deoxy-d-glucose in polycystic kidney disease: from animal models to humans. Journal of Nephrology, 2017, 30, 511-519.	0.9	28
40	Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease. Giornale De Techniche Nefrologiche & Dialitiche, 2017, 29, 80-84.	0.1	2
41	Deciphering Variability of PKD1 and PKD2 in an Italian Cohort of 643 Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Scientific Reports, 2016, 6, 30850.	1.6	28
42	Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy. Nephron, 2016, 132, 15-24.	0.9	60
43	The MEST score provides earlier risk prediction in lgA nephropathy. Kidney International, 2016, 89, 167-175.	2.6	190
44	Advances in Genetics of Immunoglobulin A Nephropathy. , 2016, , 19-42.		0
45	Geometry-independent assessment of renal volume in polycystic kidney disease from magnetic resonance imaging. , 2015, 2015, 3081-4.		2
46	Corticosteroids in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2015, 26, 2248-2258.	3.0	187
47	Reliability of Total Renal Volume Computation in Polycystic Kidney Disease From Magnetic Resonance Imaging. Academic Radiology, 2015, 22, 1376-1384.	1.3	12
48	New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney International, 2015, 88, 974-989.	2.6	211
49	Can tonsillectomy modify the innate and adaptive immunity pathways involved in IgA nephropathy?. Journal of Nephrology, 2015, 28, 51-58.	0.9	23
50	Comment on the Paper: Â‘Novel Approach to Estimate Kidney and Cyst Volumes Using Mid-Slice Magnetic Resonance Images in Polycystic Kidney Disease'. American Journal of Nephrology, 2014, 39, 163-164.	1.4	2
51	Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney International, 2014, 86, 828-836.	2.6	373
52	Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nature Genetics, 2014, 46, 1187-1196.	9.4	505
53	Lipoprotein Glomerulopathy Associated with a Mutation in Apolipoprotein E. Clinical Medicine Insights: Case Reports, 2013, 6, CCRep.S12209.	0.3	12
54	Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 2012, 367, 2407-2418.	13.9	1,267

#	Article	IF	Citations
55	Coexistence of Different Circulating Anti-Podocyte Antibodies in Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1394-1400.	2.2	123
56	Identification and Characterization of a New Autoimmune Protein in Membranous Nephropathy by Immunoscreening of a Renal cDNA Library. PLoS ONE, 2012, 7, e48845.	1.1	14
57	Interstitial fluid obtained from kidney biopsy as new source of renal biomarkers. Journal of Nephrology, 2011, 24, 329-337.	0.9	4
58	Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens. Journal of Proteomics, 2011, 74, 2008-2017.	1.2	101
59	Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nature Genetics, 2011, 43, 321-327.	9.4	528
60	Pregnancy and Progression of IgA Nephropathy: Results of an Italian Multicenter Study. American Journal of Kidney Diseases, 2010, 56, 506-512.	2.1	53
61	Urine Proteome Analysis May Allow Noninvasive Differential Diagnosis of Diabetic Nephropathy. Diabetes Care, 2010, 33, 2409-2415.	4.3	83
62	Genetic Variation of DKK3 May Modify Renal Disease Severity in ADPKD. Journal of the American Society of Nephrology: JASN, 2010, 21, 1510-1520.	3.0	59
63	Proteomic analysis of urine from proteinuric patients shows a proteolitic activity directed against albumin. Nephrology Dialysis Transplantation, 2009, 24, 1672-1681.	0.4	30
64	Unified Criteria for Ultrasonographic Diagnosis of ADPKD. Journal of the American Society of Nephrology: JASN, 2009, 20, 205-212.	3.0	590
65	Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein) Tj ETQq1 1 0.784314 rgBT /Ove	0.4	32
66	Genome-Wide Linkage Scan of a Large Family with IgA Nephropathy Localizes a Novel Susceptibility Locus to Chromosome 2q36. Journal of the American Society of Nephrology: JASN, 2007, 18, 2408-2415.	3.0	112
67	Influence of ACE I/D gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease: a meta-analysis. Nephrology Dialysis Transplantation, 2006, 21, 3155-3163.	0.4	35
68	A validated model of disease progression in IgA nephropathy. Journal of Nephrology, 2006, 19, 32-40.	0.9	7
69	Progressive Loss of Renal Function Is an Age-Dependent Heritable Trait in Type 1 Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 755-762.	3.0	84
70	Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis. Kidney International, 2003, 64, 149-159.	2.6	56
71	Genotype-Renal Function Correlation in Type 2 Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2003, 14, 1164-1174.	3.0	129
72	Epidermal growth factor receptor polymorphism and autosomal dominant polycystic kidney disease. Journal of Nephrology, 2003, 16, 110-5.	0.9	2

#	Article	IF	Citations
73	Which criteria should we use to end isolation in hemodialysis patients with COVID-19?. CKJ: Clinical Kidney Journal, 0, , .	1.4	3